CA-NOMINAL
22.4.2024 19:29:30 CEST | Business Wire | Press release
Nominal, a company specializing in creating end-to-end data analysis solutions for industrial engineering teams, emerged from stealth to provide a faster, more reliable way to review test data and validate mission-critical systems. The startup raised $7.5M in Seed funding led by Lux Capital with support from Founders Fund and $20M in their Series A led by General Catalyst. Additional investors include Haystack VC, XYZ Ventures, Human Capital, Box Group, and Overmatch.
Nominal specializes in creating software solutions for the Aerospace, Defense, Industrial Machinery, Transportation, and Energy sectors with various partnerships across the U.S. government. The company is led by co-founder and CEO Cameron McCord, who has extensive experience in the private sector at prominent startups Anduril, Applied Intuition, and Saildrone and as a venture capitalist, and in the public sector as a veteran Nuclear Submarine Officer and Congressional Liaison for the Navy. McCord works closely with his co-founders Bryce Strauss, a former Lockheed Martin Space division systems engineer who worked on inter-planetary robotic missions and building software tools for engineers, and Jason Hoch, an experienced software engineer who has diverse experience creating data products for startups, Fortune 500 companies, and governments.
Nominal's platform is designed to handle sensitive government and industrial data. The company's leadership team brings over 15 years of combined experience in both hardware and software from organizations like SpaceX, Palantir, Anduril, Applied Intuition, NASA, Microsoft, and more.
“Building trust in industrial systems and the data that these systems generate is core to our mission at Nominal. As aerospace, defense, and industrial systems have rapidly become more complex and software-defined, the software tools and infrastructure that engineers and operators use to make sense of and validate these systems have lagged in a costly and dangerous way.” Cameron McCord, Co-founder and CEO of Nominal said, “We’re choosing now to come out of stealth because we feel ready to accelerate our mission to help engineers that develop, test, and validate mission-critical industrial systems. We are on an industrial software collision course. Time is ticking - for our commercial customers, this means getting a product safely to market faster, and for our government customers, it means fielding reliable and tested systems for any mission.”
With Nominal, teams can quickly test and deploy their complex hardware systems. Nominal is dedicated to providing a robust, end-to-end solution that simplifies workflows, fosters collaboration, and seamlessly scales with the evolving needs of its valued customers and partners. Nominal also enables teams and organizational-level collaboration and visibility to reflect the multidisciplinary and iterative nature of engineering. The more people in an engineering organization who can view a comprehensive data story, the better the understanding and insights gained.
"When we first met Nominal, what stood out to us was the intentionality by which Cameron, Bryce, and Jason are building the company. Nominal’s modern software suite is purpose-built for hardware engineers to manage the complex workflows of testing and developing high-stakes, breakthrough hardware systems. By hitting the industrial software collision course head-on, we believe Nominal can help unlock a renaissance of industrial innovation,” said Paul Kwan, Managing Partner, General Catalyst.
Nominal is utilizing this latest infusion of capital to uphold its commitment to delivering innovative solutions to the defense and aerospace sectors, including the rollout of its full-stack data analysis solution designed to facilitate and expedite the process of analyzing and reviewing test data for engineering teams. Beyond new product initiatives to meet growing customer demands, the company also intends to grow its teams and enhance its security and deployment capabilities.
About Nominal
Nominal is igniting the next industrial revolution. By allowing for rapid and accurate review of test data and the validation of critical systems through its comprehensive data analysis platform, Nominal provides modern workflows specifically tailored to the needs of engineering teams that develop, validate, and monitor hardware. At Nominal, we believe hardware engineers deserve the world’s best software. We are fully committed to helping our users more efficiently and effectively test and deploy mission-critical systems that will change the world. Nominal currently supports mission-critical data analysis and testing at companies across the aerospace, defense, energy, and industrial spheres including Varda Space, Muon Space, REGENT, Radiant Nuclear, the U.S. Air Force, and others. We are supported by leading venture investors such as General Catalyst, Lux Capital, Founders Fund, Haystack, XYZ Ventures, Human Capital, BoxGroup, and Overmatch. To learn more about Nominal and its innovative solutions, please visit nominal.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240418799842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom